A Shared Care Agreement (SCA) is a local guideline that outlines the responsibilities of the specialist and the GP for the prescribing and monitoring of medicines, once a patient is stable on that medicine.

Below is a list of approved Shared Care Agreements for Lincolnshire:
 

Shared Care Agreements

Title
SCA ADHD Sept 2019-2022

Description

SHARED CARE GUIDELINE:

Methylphenidate, atomoxetine, dexamfetamine, lisdexamfetamine and guanfacine in the management of Attention Deficit Hyperactivity Disorder (ADHD).

The shared care protocol covers the initiation and review of treatment in children and adolescents with ADHD.

THIS PROTOCOL DOES NOT COVER THE INITIATION OF NEW TREATMENT IN ADULT PATIENTS.

SCA Atrial Fibrillation (Dronedarone) Nov 2018-2020

Description

SHARED CARE GUIDELINE:

Dronedarone for the treatment of patients with non-permanent atrial fibrillation.

SCA Chronic Pain & Palliative Care (Ketamine) Nov 2018-2020

Description

SHARED CARE GUIDELINE:

Ketamine for use in palliative care for the management of pain unresponsive to standard therapies and as a third/fourth-line choice for the management of chronic neuropathic pain that has failed to respond to alternative treatments.

This protocol does not cover the use of ketamine injection prescribed to be administered sublingually.

All prescribing of sublingual ketamine will be retained by United Lincolnshire Hospitals.

This protocol only covers the oral administration of ketamine.

SCA Dementia March 2019-2022

Description

SHARED CARE AGGREMENT:

Dementia.

Acetyl Cholinesterase Inhibitors and Memantine Prescribing Arrangements.

Traffic Light Category: Amber 1.

SCA Dermatology (Azathiopine, Ciclosporin, Methotrexate) Nov 2018-2020

Description

SHARED CARE GUIDELINE for AZATHIOPRINE, CICLOSPORIN and METHOTREXATE oral in the treatment of dermatological conditions.

SCA Management of Inflammatory Bowel Disease (Azathioprine, Marcaptopurine) Sept 2019-2022

Description

SHARED CARE GUIDELINE: Management of Inflammatory Bowel Disease – azathioprine and mercaptopurine.

SCA Orthostatic Hypotension (Midodrine, Bramox) Nov 2018-2020

Description

SHARED CARE GUIDELINE:

Bramox - Midodrine 2.5mg and 5mg tablets for the treatment of severe orthostatic hypotension due to autonomic dysfunction and unlicensed use for the treatment of severe orthostatic hypotension or syncope in the absence of autonomic dysfunction.

SCA Respiratory (Methotrexate) March 2019-2022

Description

SHARED CARE GUIDELINE:

METHOTREXATE Unlicensed use in the management of sarcoidosis.

SCA Rheumatology (Hydroxychloroquine) Nov 2018-2020

Description

SHARED CARE GUIDELINE:

Hydroxychloroquine for treatment of active rheumatoid arthritis including juvenile idiopathic arthritis and systemic and discoid lupus erythematosus.

SCA Rheumatology (Leflunomide) Nov 2018-2020

Description

SHARED CARE GUIDELINE:

Leflunomide treatment of active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

SCA Rheumatology (Methotrexate) Nov 2018-2020

Description

SHARED CARE GUIDELINE: METHOTREXATE

Licensed Indications Moderate to severe active classical or definite rheumatoid arthritis.

Unlicensed indications – Psoriatic arthritis and connective tissue disease.

SCA Rheumatology (Sulfasalazine) Nov 2018-2020

Description

SHARED CARE GUIDELINE:

SULFASALAZINE for the treatment of active Rheumatoid Arthritis.

SCA Sleep Disorders in Children (Melatonin) Sept 2019-2021

Description

SHARED CARE GUIDELINE:

The use of melatonin in the treatment of severe sleep disorders in children and adolescents with neurological or neuro-developmental disorders.

This shared care protocol covers the initiation of treatment in children and adolescents including those with learning disabilities.

THIS PROTOCOL DOES NOT COVER THE INITIATION OF NEW TREATMENT IN ADULT AND ELDERLY PATIENTS OVER THE AGE OF 55 YEARS.

This protocol however can be extended to cover the on-going therapy for existing patients once they have reached 18 years of age who are retained in services.